Tumor Targeting Properties of Indium-111 Labeled Genetically Engineered Fab′ and F(ab′)2 Constructs of Chimeric Tumor Necrosis Treatment (chTNT)-3 Antibody

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 6, 2003, Pages 931-940

  Khawli, Leslie A ^a   Alauddin, Mian M ^a   Hu, Peisheng ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biodistribution; F(ab )2; Imaging; Monoclonal antibody; Pharmacokinetics; Tumor necrosis treatment

Indexed keywords

CHIMERIC TUMOR NECROSIS TREATMENT 3 ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IODINE 125; MONOCLONAL ANTIBODY; PENTETATE INDIUM IN 111; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CHIMERA; GENETIC ENGINEERING; IMAGING SYSTEM; IMMUNOREACTIVITY; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCINTILLATION CAMERA; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR NECROSIS;

EID: 0347569578     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322702897     Document Type: Article

References (41)

1. Stigbrand T, Ullen A, Sandstrom P, et al. Twenty years with monoclonal antibodies: State of the art - Where do we go? Acta Oncol 1996;35:259.
2. Von Mehren M, Weiner LM. Monoclonal antibody-based therapy. Curr Opin Oncol 1996;8:493.
3. Zhu H, Baxter LT, Jain RK. Potential and limitations of radioimmunodetection and radio immunotherapy with monoclonal antibodies. J Nucl Med 1997;38:731.
4. Milstein C, Waldmann H. Optimism after much pessimism: What next? Curr Opin Immunol 1999;11:589.
5. Behr TM, Memtsoudis S, Sharkey RM, et al. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy. Int J Cancer 1998;77:787.
6. 2, and Fab′ anti-carcinoembryonic antigen antibodies labeled with 99mTc: The role of metabolism and kinetics. Cancer Res 1995;55:5777.
7. Larson SM. Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med 1985;26:538.
8. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993;94:297.
9. 2 fragments for radioimmuno-imaging of human colon cancer in nude mice. Nucl Med Biol 1993;20:243.
10. Colcher D, Pavlikova G, Beresford G, et al. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 1998;42:225.
11. Carter P, Kelley RF, Rodrigues ML, et al. High-level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology 1992;10:163.
12. 2 formation in Escherichia coli and for improved in vivo stability. J Immunol 1993;151:6954.
13. 2 molecules made from Escherichia coli produced Fab′ with hinge sequences conferring increased serum survival in an animal model. J Immunol Meth 1998;217:1.
14. Geissler F, Anderson SK, Press O. Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Cell Immunol 1991;137:96.
15. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: Novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med 2001;42:1519.
16. Kobayashi H, Wu C, Kim M-K, et al. Evaluation of the in vivo biodistribution of Indium-11 and Ytrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. Bioconjugate Chem 1999;10:103.
17. 111In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med 2001;42:1530.
18. Epstein A, Chen F-M, Taylor C. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988;48:5842.
19. Miller GK, Naeve GS, Gaffar SA, Epstein AL. Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones. Hybridoma 1993;12:689.
20. Homick J, Sharifi J, Khawli L, et al. A new chemically modified chimeric monoclonal antibody directed against DNA for the immunotherapy of solid tumors. Cancer Biother Radiopharm 1998;13:255.
21. Khawli LA, Mizokami MM, Sharifi J, et al. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modifications with biotin. Cancer Biother Radiopharm 2002;17:359.
22. 2 fragments of chimeric TNT-3 expressed in mammalian cells. Hybridoma and Hybridomics 2002;21:11.
23. Ohsugi Y, Gershwin ME, Owens RB, Nelson-Rees WA. Tumorigenicity of human malignant lymphoblasts: Comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X-irradiated nude mice. J Natl Cancer Inst 1980;65:715.
24. Hnatowich DJ, Layne WW, Childs RL, et al. Radioactive labeling of antibody: A simple and efficient method. Science 1983;220:613.
25. Gaffar S, Chen F-M, Liu C, Epstein A. Cell based radioimmunoassays to quantitate the immunoreactivity of TNT monoclonal antibodies directed against intracellular antigens. J Immunoassay 1991;12:1.
26. Zuckier LS, Georgescu L, Chang CJ, et al. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 1994;73:794.
27. Hu P, Glasky MS, Yun A, et al. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res 1996;56:4998.
28. 2, and Fab′ in mice. Cancer Res 1986;46:3969.
29. Behr TM, Becker WS, Bair H-J, et al. Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 1995;36:430.
30. H2 domain and directed against the disialoganglioside GD2. Proc Nat Acad Sci USA 1990;87:5702.
31. Slavin-Chiorini DC, Kashmiri SVS, Schlom J, et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995;55:(suppl.)5957.
32. 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen. Clin Cancer Res 2000;6:4921.
33. Hornick JL, Sharifi J, Khawli LA, et al. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. J Nucl Med 2000;41:355.
34. Ghetie V, Ward ES. FcRn: The MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997;18:592.
35. Khawli LA, Biela BH, Hu P, Epstein AL. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybridoma and Hybridomics 2003;22:1.
36. Buschbaum DJ. Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 1995;55:5729s.
37. Epstein AL, Khawli LA, Hu P. Tumor necrosis treatment and imaging of solid tumors. In: Torchilin V, Muzykantov V, eds. Biomedical Aspects of Drug Targeting. Norwell, MA: Kluwer Academic Publishers, 2002:249.
38. Philpott GW, Schwarz SW, Anderson CJ, et al. RadioimmunoPET: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995;36:1818.
39. 89Zr-labeled monoclonal antibodies. J Nucl Med 2003;44:1271.
40. Lee FT, Scott AM. Immuno-PET for tumor targeting. J Nucl Med 2003;44:1282.
41. 64Cu for tumor imaging and therapy. J Nucl Med 2003;44:1284.